Immune cell functions in pancreatic cancer.
Immune cell functions in pancreatic cancer.
复制标题
DOI：
10.1615/critrevimmunol.v20.i5.20
复制
发表时间：
2000
影响因子：
1.3
通讯作者：
J. Plate;J. Harris
中科院分区：
文献类型：
--
作者：
J. Plate;J. Harris
在美国，胰腺癌每年导致近29,000人死亡，与被诊断患有这种疾病的人数一样多。化学治疗对阻止疾病的发展无效。然而，在过去的24年中，胰腺癌受试者对胰腺肿瘤细胞的特异性免疫已被反复证明。然而，用生物疗法扩大和增强肿瘤特异性免疫的尝试尚未取得成功。问题仍然存在，“为什么特异性免疫不能调节胰腺癌的生长？“肿瘤细胞已经进化出针对免疫的保护机制的想法是在几年前提出的，最近被一些研究实验室重新审视。在胰腺癌中，已经检测到由肿瘤环境产生并用于保护肿瘤环境的可溶性因子，并且这些可溶性因子通常分布到受害者的循环系统中，在那里它们可以影响更广泛的免疫抑制。然而，这些可溶性因子的性质仍然存在争议，因为有些因子也作为肿瘤抗原，被相同的T细胞识别，这些T细胞可能被它们灭活。除非通过基础和转化研究直接解决肿瘤源性免疫抑制产品的问题，否则胰腺癌的成功生物素治疗可能不会到来。
Pancreatic cancer kills nearly 29,000 people in the United States annually-as many people as are diagnosed with the disease. Chemotherapeutic treatment is ineffective in halting progression of the disease. Yet, specific immunity to pancreatic tumor cells in subjects with pancreatic cancer has been demonstrated repeatedly during the last 24 years. Attempts to expand and enhance tumor-specific immunity with biotherapy, however, have not met with success. The question remains, "Why can't specific immunity regulate pancreatic cancer growth?" The idea that tumor cells have evolved protective mechanisms against immunity was raised years ago and has recently been revisited by a number of research laboratories. In pancreatic cancer, soluble factors produced by and for the protection of the tumor environment have been detected and are often distributed to the victim's circulatory system where they may effect a more generalized immunosuppression. Yet the nature of these soluble factors remains controversial, since some also serve as tumor antigens that are recognized by the same T cells that may become inactivated by them. Unless the problem of tumor-derived immunosuppressive products is addressed directly through basic and translational research studies, successful biotherapeutic treatment for pancreatic cancer may not be forthcoming.